|Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis|
E Nuermberger, S Tyagi, R Tasneen, KN Williams, D Almeida, I Rosenthal, ...
Antimicrobial agents and chemotherapy 52 (4), 1522-1524, 2008
|Targeting DnaN for tuberculosis therapy using novel griselimycins|
A Kling, P Lukat, DV Almeida, A Bauer, E Fontaine, S Sordello, ...
Science 348 (6239), 1106-1112, 2015
|Evolution of extensively drug-resistant tuberculosis over four decades: whole genome sequencing and dating analysis of Mycobacterium tuberculosis isolates from KwaZulu-Natal|
KA Cohen, T Abeel, AM McGuire, CA Desjardins, V Munsamy, TP Shea, ...
PLoS Med 12 (9), e1001880, 2015
|Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis|
E Nuermberger, I Rosenthal, S Tyagi, KN Williams, D Almeida, ...
Antimicrobial agents and chemotherapy 50 (8), 2621-2625, 2006
|Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor|
S Gupta, S Tyagi, DV Almeida, MC Maiga, NC Ammerman, WR Bishai
American journal of respiratory and critical care medicine 188 (5), 600-607, 2013
|Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance|
CA Desjardins, KA Cohen, V Munsamy, T Abeel, K Maharaj, BJ Walker, ...
Nature genetics 48 (5), 544-551, 2016
|Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis|
IM Rosenthal, R Tasneen, CA Peloquin, M Zhang, D Almeida, KE Mdluli, ...
Antimicrobial agents and chemotherapy 56 (8), 4331-4340, 2012
|Incidence of multidrug-resistant tuberculosis in urban and rural India and implications for prevention|
D Almeida, C Rodrigues, ZF Udwadia, A Lalvani, GD Gothi, P Mehta, ...
Clinical infectious diseases 36 (12), e152-e154, 2003
|Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice|
JH Grosset, S Tyagi, DV Almeida, PJ Converse, SY Li, NC Ammerman, ...
American journal of respiratory and critical care medicine 188 (5), 608-612, 2013
|Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis|
S Tyagi, NC Ammerman, SY Li, J Adamson, PJ Converse, RV Swanson, ...
Proceedings of the National Academy of Sciences 112 (3), 869-874, 2015
|Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis|
D Almeida, E Nuermberger, R Tasneen, I Rosenthal, S Tyagi, K Williams, ...
Antimicrobial agents and chemotherapy 53 (10), 4178-4184, 2009
|Mutations in pepQ confer low-level resistance to bedaquiline and clofazimine in Mycobacterium tuberculosis|
D Almeida, T Ioerger, S Tyagi, SY Li, K Mdluli, K Andries, J Grosset, ...
Antimicrobial agents and chemotherapy 60 (8), 4590-4599, 2016
|High Incidence of the Beijing Genotype among Multidrug-Resistant Isolates of Mycobacterium tuberculosis in a Tertiary Care Center in Mumbai, India|
D Almeida, C Rodrigues, TF Ashavaid, A Lalvani, ZF Udwadia, A Mehta
Clinical infectious diseases 40 (6), 881-886, 2005
|Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?|
IM Rosenthal, M Zhang, D Almeida, JH Grosset, EL Nuermberger
American journal of respiratory and critical care medicine 178 (9), 989-993, 2008
|Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis|
RV Swanson, J Adamson, C Moodley, B Ngcobo, NC Ammerman, ...
Antimicrobial agents and chemotherapy 59 (6), 3042-3051, 2015
|Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?|
PJ Converse, EL Nuermberger, DV Almeida, JH Grosset
Future Microbiology 6 (10), 1185-1198, 2011
|Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection|
JWC Alffenaar, WA Nienhuis, F De Velde, AT Zuur, AMA Wessels, ...
Antimicrobial agents and chemotherapy 54 (9), 3878-3883, 2010
|In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis|
D Almeida, E Nuermberger, S Tyagi, WR Bishai, J Grosset
Antimicrobial agents and chemotherapy 51 (12), 4261-4266, 2007
|Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice|
M Zhang, SY Li, IM Rosenthal, DV Almeida, Z Ahmad, PJ Converse, ...
American journal of respiratory and critical care medicine 183 (9), 1254-1261, 2011
|Microbiological, histological, immunological, and toxin response to antibiotic treatment in the mouse model of Mycobacterium ulcerans disease|
FS Sarfo, PJ Converse, DV Almeida, J Zhang, C Robinson, ...
PLoS Negl Trop Dis 7 (3), e2101, 2013